MATERIALS
THAT POWER
THE FUTURE
About Us
Powering the nuclear
renaissance with
critical materials
Quantum Leap Energy (QLE) delivers secure, reliable nuclear materials through proprietary enrichment technologies and a robust supply chain. We are developing a scalable and agile solution to meet the world’s accelerating nuclear energy needs.
Superior Technical
Performance
Our Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE) Technology are targeting to deliver higher selectivity, enabling faster, more efficient isotope production versus incumbent technology.
Scalable &
Modular Design
Flexibly situated with rapid capacity expansion leading to faster deployment compared to traditional centrifuge technology.
Integrated & Efficient
Value Chain
We are expanding our capabilities across the nuclear fuel cycle; including conversion, enrichment, deconversion & waste treatment with the intent to reduce capital intensity.
Strategic
Advantage
By applying advanced technologies, we aim to increase the availability and reliability of enriched materials while strengthening domestic supply and reducing foreign dependence.
Empowering
energy transition
and independence through
next-generation nuclear fuel
cycle technologies.
The science behind progress
A laser-based isotope separation process with significantly higher selectivity than legacy methods, enables efficient production of HALEU and enriched lithium isotopes.
Our superior modular design, low capital cost, and fast construction cycle as compared to traditional processes, allows for easy plant expansion.
Using high-velocity tangential injection to create dual vortex flows, ASP separates isotopes efficiently within a stationary tube, enabling precise, scalable enrichment for lighter atomic-mass gases.
Our proprietary gas-based isotope technology with minimal moving parts, offers lower capital and operating costs than centrifuges.
Materials at the foundation of change
Nuclear Waste Management
Turning nuclear waste into significant value
Depleted tails from uranium enrichers represent a growing waste challenge. QLE’s advanced technologies aim to process this material into HALEU, offering a responsible solution at highly competitive prices.
Building energy security for the world
United Kingdom
United States
South Africa
TerraPower Partnership
Long-term HALEU supply agreements and financing supporting major commercial deployment.
Fermi America Joint Venture
Collaboration on research, development, and construction of advanced enrichment facility in Texas.
South African Nuclear Energy Corporation (Necsa)
Collaboration on research, development, and commercial production of advanced nuclear fuels in Pretoria, South Africa.
Leadership
Leading the new energy era
Dr. Pretorius has served as our Chief Executive Officer since May 2025. He has spent the last decade and a half as a practicing chemical engineer, facilitating technology scale-up for multiple organizations globally.
Prior to joining QLE, he was a pilot plant Project Engineer, Hydrometallurgy Department Manager and Development Engineer at Brimstone, a developer of next-generation industrial processes optimized for economics, efficiency, and sustainability. Previously, he worked as founder, technical director and CEO of Free Radical Process Design, a global consulting firm specializing in the design, development and economic evaluation of engineering technologies and processes. He was also the co-founder and CEO of Rare Earth Refiners from February 2019 to February 2025.
Dr. Pretorius has a B. Eng, B. Eng (Hons) and an M. Eng in Chemical Engineering from the University of Pretoria, as well as a Ph.D. in Chemical Engineering from the University of Pretoria, where he specialized in fluorochemical engineering and developed a novel fluorination process in the critical materials value-chain.
Ryno Pretorius, Ph.D.
Chief Executive Officer
Mr. Cunniffe has served as our Chief Financial Officer since October 2025. Prior to joining QLE, from April 2023 to October 2025, Mr. Cunniffe served as Managing Director, UK at Danforth Advisors, a life science financial strategy consultancy.
In his capacity as a consultant, Mr. Cunniffe provided consulting and advisory services to ASP Isotopes under the terms of a consulting agreement with Danforth Advisors.
Prior to joining Danforth Advisors, from October 2021 to May 2022, Mr. Cunniffe was Chief Financial Officer of Axovia Therapeutics Ltd., a UK-based gene therapy company focused on developing treatments for ciliopathies.
Before Axovia Therapeutics, Mr. Cunniffe held finance leadership roles at biopharmaceutical companies ATAI Life Sciences AG, Neurogene Inc. and Seqirus, from November 2019 to September 2021, July 2018 to June 2019, and August 2016 to August 2018, respectively. Mr. Cunniffe holds a Master’s degree in Finance from London Business School and is currently pursuing a Master’s in Cell and Gene Therapy at UCL.
Michael Cunniffe
Chief Financial Officer
News & Media
What’s next in nuclear?
Connect
Take the
Quantum Leap
We’re committed to clear dialogue, strong collaboration, and advancing the future of nuclear energy with confidence and integrity. Reach out to us today.
Inquiring for:
